Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 23, 2026Investment Snapshot
- P/B of 6.02 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -128.4%
- Revenue growing at 53% annually
Lineage Cell Therapeutics, Inc. Common Stock (LCTX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the AMEX , with a market capitalisation of $324 million . Key value metrics: P/B ratio 6.02, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Lineage Cell Therapeutics, Inc. Common Stock — Fundamental Analysis Summary
On financial health, LCTX shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -128.4% (sector average: -20.6%), and elevated leverage with a debt-to-equity ratio of 1.55.
StockPik's composite Value Score for LCTX is 27/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
LCTX reports a high gross margin of 96.5% (sector average: 40.1%) and a negative operating margin of -389.4%.
LCTX shows revenue growing at 53% year-over-year, with earnings declining at 241%.